Hematologist, at Gülhane Training And Research Hospital, Turkey.
Dr. Selim Sayın is a dedicated hematologist with a specialized focus in bone marrow transplantation and clinical hematology. Currently serving at the Gülhane Educational and Research Hospital in Ankara, he plays a pivotal role in the Hematology and Bone Marrow Transplantation Unit. His medical career spans over a decade, underpinned by a strong foundation in internal medicine and subspecialty training in hematology. Dr. Sayın is actively engaged in cutting-edge clinical trials involving immunotherapy and stem cell transplantation, contributing to the advancement of therapeutic strategies in hematologic diseases. Beyond clinical practice, he has co-authored several peer-reviewed publications and is a member of the Turkish Hematology Association. His commitment to evidence-based medicine and translational research ensures he remains at the forefront of hematologic innovation, delivering compassionate and high-quality care to his patients. 🩸📚
Professional Profile
Scopus
🎓 Education
Dr. Sayın’s educational journey in medicine began at the Gülhane Military Medical Academy, where he completed his residency in Internal Medicine, laying a robust foundation for his future specialization. His interest in hematology and patient-centered cancer care led him to pursue a Hematology Fellowship at the Gülhane Educational and Research Hospital, a nationally recognized center for hematologic research and treatment. Through rigorous academic training and hands-on clinical exposure, Dr. Sayın developed expertise in managing complex hematological conditions, including leukemia, lymphoma, multiple myeloma, and bone marrow failure syndromes. His educational path reflects a commitment to lifelong learning and clinical excellence, further enhanced by continuous participation in international clinical trials and advanced training in bone marrow transplantation protocols. 🎓🔬
🏥 Experience
Dr. Selim Sayın has amassed diverse experience across top-tier medical institutions in Turkey. His early professional years were spent at Çiğiltepe Askeri Dispanseri, where he honed his skills in general internal medicine and patient care. He later served at Keçiören Educational and Research Hospital, expanding his clinical scope and engaging in multidisciplinary hematology care. Currently, he holds a key position at Gülhane Educational and Research Hospital in Ankara within the Hematology and Bone Marrow Transplantation Unit. His role involves managing complex hematological malignancies, overseeing transplantation procedures, and mentoring junior medical staff. In all his professional endeavors, Dr. Sayın has consistently demonstrated a passion for precision medicine and patient safety. His multidisciplinary approach and adherence to evidence-based protocols underscore his standing as a leading figure in Turkish hematology. 🏨🧬
🔬 Research Interest
Dr. Selim Sayın’s research interests lie at the intersection of clinical hematology, bone marrow transplantation, and immune thrombocytopenia therapies. He has been an active investigator in several multinational, Phase 3 clinical trials, including the ADVANCE trial (ARGX-113-1801), evaluating the efficacy and safety of Efgartigimod in treating adult primary immune thrombocytopenia. He also contributes to the ITHACA study, comparing novel therapies like isatuximab with standard regimens for high-risk smoldering multiple myeloma. His research is rooted in improving patient outcomes through tailored therapeutic approaches, biomarker-guided therapy, and apheresis-related innovations. Dr. Sayın is particularly interested in translational research that bridges the gap between clinical trials and routine patient care. His work consistently aims to redefine hematologic treatment standards, reflecting a commitment to innovation and scientific rigor. 🧪🧠
🏆 Awards
Dr. Sayın has consistently demonstrated excellence in both clinical service and academic contribution, making him a strong nominee for prestigious hematology awards. While formal accolades are in progress, his impactful participation in high-profile, peer-reviewed research and international clinical trials distinguishes him in the field. As a co-author on multiple collaborative multicenter studies, he has earned recognition for innovative approaches to graft-versus-host disease prophylaxis and stem cell mobilization prediction models. His contributions reflect not only research excellence but also a dedication to improving quality of care in hematologic disorders. With ongoing involvement in pioneering trials and Turkish Hematology Association activities, Dr. Sayın is poised to receive further honors in clinical science and patient-focused research. 🥇📖
📄Top Noted Publications
Dr. Sayın has co-authored impactful studies in leading journals, advancing knowledge in hematopoietic stem cell transplantation and therapeutic apheresis:
1. Comparison of Cyclophosphamide-Based Graft Versus Host Disease Prophylaxis After Allogeneic Stem Cell Transplantation
Journal: International Journal of Hematology-Oncology and Stem Cell Research, 2024, 18(3): 227–239
Summary:
This study evaluates the efficacy and safety of cyclophosphamide-based GVHD prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). It compares post-transplant cyclophosphamide (PTCy) protocols with conventional prophylactic regimens like calcineurin inhibitors (e.g., cyclosporine or tacrolimus) plus methotrexate.
Key outcomes analyzed include:
Findings:
-
PTCy significantly reduces grade II–IV acute GVHD incidence
-
Comparable relapse rates and OS
-
Better tolerability and lower infection rates in some subgroups
🔁 Cited by:
Recent articles on GVHD management strategies, especially those investigating low-toxicity prophylaxis regimens and haploidentical transplant protocols.
2. Apheresis Product Total CD34+ Cell Count Prediction at Peripheral Stem Cell Collection
Journal: Transplant Immunology, 2024, 86: 102111
Summary:
The paper introduces a predictive model for estimating total CD34+ cell yield in peripheral blood stem cell (PBSC) collections. It analyzes donor characteristics (e.g., age, weight, pre-apheresis CD34+ count) and apheresis parameters (blood volume processed, number of sessions) to develop a multivariable regression model.
Key contributions:
-
Establishes a practical tool for clinicians to predict yield
-
Optimizes collection strategies
-
Minimizes need for repeat apheresis sessions
Findings:
🔁 Cited by:
Papers on mobilization protocols, stem cell harvest optimization, and algorithmic prediction tools for transplant planning.
3. Therapeutic Apheresis Treatment in Rheumatic Diseases: Single-Center Experience
Journal: Therapeutic Apheresis and Dialysis, 2024
Summary:
This retrospective study presents a single-center experience of using therapeutic apheresis (primarily plasma exchange (PLEX) and immunoadsorption) in patients with rheumatic autoimmune diseases such as SLE, systemic sclerosis, and vasculitis.
It covers:
-
Indications for apheresis
-
Number of sessions per disease type
-
Clinical response rates and safety profiles
Findings:
-
High efficacy in crisis-phase autoimmune flares (e.g., lupus nephritis, ANCA vasculitis)
-
Apheresis well-tolerated with minimal complications
🔁 Cited by:
Clinical practice guidelines in autoimmune disease management, particularly regarding refractory cases or those unresponsive to immunosuppressants.
Conclusion
Dr. Selim Sayın demonstrates clear strengths as a clinician-scientist, particularly in collaborative, translational hematology research. His recent high-quality publications and participation in advanced clinical trials position him as a promising mid-career researcher. While his contributions are significant, to be a top-tier candidate for the Best Researcher Award, further development in leadership roles, independent authorship, and research visibility would strengthen his case.